Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Myeloperoxidase (MPO)

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 83876 refers to the measurement of myeloperoxidase (MPO) levels in a blood sample. Myeloperoxidase is an enzyme produced by white blood cells, specifically neutrophils, and serves as a biomarker for cardiovascular risk assessment. The procedure involves obtaining a blood sample through a venipuncture, which is a standard method for drawing blood. This test is particularly significant as it helps identify patients who may be at an increased risk for myocardial infarction, commonly known as a heart attack, and those who may require cardiac revascularization procedures, which are interventions aimed at restoring blood flow to the heart. The quantification of myeloperoxidase is typically performed using an enzyme-linked immunosorbent assay (ELISA), a laboratory technique that allows for the precise measurement of this biomarker in the blood plasma. Elevated levels of myeloperoxidase in patients presenting with chest pain can indicate a higher likelihood of experiencing major cardiac events, making this test a valuable tool in the early identification and management of cardiovascular conditions.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The myeloperoxidase (MPO) test, represented by CPT® Code 83876, is indicated for the following conditions:

  • Risk Assessment for Myocardial Infarction This test is utilized to identify patients who may be at an increased risk for experiencing a myocardial infarction, commonly known as a heart attack.
  • Need for Cardiac Revascularization The MPO test helps determine which patients may require cardiac revascularization procedures, aimed at restoring adequate blood flow to the heart.
  • Evaluation of Chest Pain Patients presenting with chest pain may undergo this test to assess the risk of major cardiac events based on elevated levels of circulating myeloperoxidase.

2. Procedure

The procedure for measuring myeloperoxidase levels involves several key steps:

  • Step 1: Venipuncture A qualified healthcare professional performs a venipuncture, which is the process of puncturing a vein to obtain a blood sample. This is typically done in a clinical setting using sterile techniques to ensure patient safety and sample integrity.
  • Step 2: Sample Collection The blood collected during the venipuncture is placed into a suitable container, often a tube that is specifically designed for plasma separation. This step is crucial as it prepares the sample for subsequent analysis.
  • Step 3: Laboratory Analysis The collected blood sample undergoes analysis in a laboratory setting, where an enzyme-linked immunosorbent assay (ELISA) is performed. This assay quantifies the level of myeloperoxidase in the blood plasma, providing critical data for evaluating cardiovascular risk.

3. Post-Procedure

After the myeloperoxidase test is completed, patients may experience minimal to no discomfort from the venipuncture. It is generally recommended that patients resume their normal activities unless otherwise advised by their healthcare provider. The results of the MPO test are typically reviewed in conjunction with other clinical findings and patient history to determine the appropriate course of action, especially if elevated levels are detected. Healthcare providers may discuss the implications of the test results with the patient, including potential further diagnostic testing or treatment options based on the identified cardiovascular risk.

Short Descr ASSAY MYELOPEROXIDASE
Medium Descr MYELOPEROXIDASE MPO
Long Descr Myeloperoxidase (MPO)
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 1
CCS Clinical Classification 233 - Laboratory - Chemistry and Hematology
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
GY Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit
GA Waiver of liability statement issued as required by payer policy, individual case
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
AY Item or service furnished to an esrd patient that is not for the treatment of esrd
G8 Monitored anesthesia care (mac) for deep complex, complicated, or markedly invasive surgical procedure
GW Service not related to the hospice patient's terminal condition
Date
Action
Notes
2011-01-01 Changed Short description changed.
2009-01-01 Added -
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"